About The Study

This study aims to investigate the safety and efficacy of TG4040 (MVA-HCV), a hepatitis C virus (HCV) therapeutic vaccine for the treatment of HCV in people who have already been diagnosed and treated and have experienced a relapse. The study will also determine whether the vaccine can decrease HCV viral load.

Study Approach

TG4040 has not been tested on people and is considered an investigational drug, meaning Health Canada, the United States Food and Drug Administration (FDA) and other regulatory agencies have not approved it for general use.

Principal Investigators

Here’s who is leading this study.

Can’t find what you’re looking for? Email ctninfo@hivnet.ubc.ca.

Dr. Jenny Heathcote